Committee Composition

  Audit Compensation Nominating and Governance
Kent Kresa Chairman of the Board   Committee Chair for Compensation Committee Member of Nominating and Governance Committee
Ronald Consiglio Independent Director Committee Chair for Audit Committee   Member of Nominating and Governance Committee
Michael Friedman, M.D. Independent Director   Member of Compensation Committee Committee Chair for Nominating and Governance Committee
Director

Michael A. Friedman, M.D. has been one of our directors since December 2003. In 2014, Dr. Friedman completed a decade of service as the President and Chief Executive Officer of the City of Hope National Medical Center. Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company. From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998. He joined the board of Celgene Corporation in February 2011 and the board of Smith & Nephew plc in April 2013. Dr. Friedman received a Bachelor of Arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School.


David H. MacCallum Independent Director Member of Audit Committee    
Henry L. Nordhoff Independent Director Member of Audit Committee    
James S. Shannon Independent Director   Member of Compensation Committee  
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director   = Financial Expert

Stock transaction information provided by EDGAR Online. MannKind Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

MNKD

Exchange:
NASDAQ GM (US Dollar)

Price: 2.81

Change: 0.16 (5.387%)

Volume: 6,224,484

Data as of
12/15/2017 04:00 PM ET .
Minimum 20 minute delay.

Refresh Quote >

Locations

Learn more about MannKind's offices in the United States

Learn More